0001562180-24-001223.txt : 20240209 0001562180-24-001223.hdr.sgml : 20240209 20240209160503 ACCESSION NUMBER: 0001562180-24-001223 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Metzger Michael A CENTRAL INDEX KEY: 0001507220 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 24614703 MAIL ADDRESS: STREET 1: C/O SYNDAX PHARMACEUTICALS, INC. STREET 2: 400 TOTTEN POND ROAD, CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-02-07 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001507220 Metzger Michael A C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 true true false false Chief Executive Officer false Common Stock 2024-02-07 4 A false 107250.00 0.00 A 124909.00 D Common Stock 2024-02-07 4 A false 39000.00 0.00 A 163909.00 D Stock Options (Right to buy) 22.28 2024-02-07 4 A false 214500.00 22.28 A 2034-02-07 Common Stock 214500.00 214500.00 D Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. 1/48th of the shares subject to the option shall vest monthly over a four-year period. /s/ Michael A. Metzger 2024-02-09